Iterum Therapeutics (ITRM) News Today $0.69 -0.03 (-4.16%) Closing price 04:00 PM EasternExtended Trading$0.69 0.00 (-0.14%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ITRM Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Iterum Therapeutics PLC: Iterum Therapeutics launches ORLYNVAH, the first and only oral penem antibiotic in the U.S.August 20, 2025 | finanznachrichten.deIterum Therapeutics announces U.S. commercial launch of ORLYNVAHAugust 20, 2025 | msn.comIterum Therapeutics launches ORLYNVAH™, the first and only oral penem antibiotic in the U.S.August 20, 2025 | globenewswire.comIterum Therapeutics PLC (NASDAQ:ITRM) Director Michael W. Dunne Purchases 15,000 SharesAugust 13, 2025 | insidertrades.comIterum Therapeutics plc (NASDAQ:ITRM) Q2 2025 Earnings Call TranscriptAugust 8, 2025 | msn.comITRM Reports ResultsAugust 5, 2025 | fool.comIterum Therapeutics Reports Second Quarter 2025 Financial ResultsAugust 5, 2025 | globenewswire.comIterum Therapeutics Q2 Earnings PreviewAugust 4, 2025 | msn.comInsights Ahead: Iterum Therapeutics's Quarterly EarningsAugust 4, 2025 | benzinga.comIterum Therapeutics to Report Second Quarter 2025 Financial Results on August 5, 2025July 29, 2025 | globenewswire.comIterum Therapeutics plc (ITRM) - Yahoo FinanceJuly 4, 2025 | finance.yahoo.comIterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635 (c) (4) - MorningstarJuly 3, 2025 | morningstar.comMIterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)July 2, 2025 | globenewswire.comIterum Therapeutics appoints Coyne as CCOJune 30, 2025 | msn.comIterum Names Christine Coyne as Chief Commercial Officer to Lead ORLYNVAH™ Launch and Commercial GrowthJune 30, 2025 | globenewswire.comITRM - Iterum Therapeutics PLC Chart - MorningstarJune 25, 2025 | morningstar.comMIterum Therapeutics Announces Publication of REASSURE Trial in NEJM EvidenceJune 25, 2025 | globenewswire.comIterum Therapeutics PLC: Iterum Therapeutics Announces Partnership for Commercialization ServicesJune 11, 2025 | finanznachrichten.deIterum Therapeutics Announces Partnership for Commercialization ServicesJune 11, 2025 | globenewswire.comIterum Therapeutics Announces Extension of Term of Promissory NoteMay 19, 2025 | globenewswire.comIterum Therapeutics PLC (ITRM) Q1 2025 Earnings Call Highlights: Strategic Moves and Financial ...May 14, 2025 | finance.yahoo.comIterum targets ORLYNVAH US launch by Q4 2025 while extending cash runway into 2026May 13, 2025 | msn.comIterum Therapeutics plc (ITRM) Q1 2025 Earnings Call TranscriptMay 13, 2025 | seekingalpha.comIterum Therapeutics Reports First Quarter 2025 Financial ResultsMay 13, 2025 | globenewswire.comA Look Ahead: Iterum Therapeutics's Earnings ForecastMay 12, 2025 | benzinga.comIterum Therapeutics to Report First Quarter 2025 Financial Results on May 13, 2025May 6, 2025 | globenewswire.comIterum Therapeutics Announces Closing of $5 Million Registered Direct Offering of Ordinary SharesApril 30, 2025 | globenewswire.comIterum Therapeutics plc Announces Definitive Agreement for $5 Million Registered Direct Offering of SharesApril 29, 2025 | quiverquant.comQIterum Therapeutics Announces $5 Million Registered Direct Offering of Ordinary SharesApril 29, 2025 | globenewswire.comIterum Therapeutics Presented a Scientific Poster at ECCMID 2025 Highlighting the Impact of Age on Antibiotic Resistance and Efficacy of AntibioticsApril 14, 2025 | globenewswire.comShort Interest in Iterum Therapeutics plc (NASDAQ:ITRM) Declines By 14.6%March 20, 2025 | marketbeat.comIterum Therapeutics Appoints New Board MembersMarch 10, 2025 | tipranks.comIterum Therapeutics faces Nasdaq non-compliance issueFebruary 14, 2025 | msn.comIterum Therapeutics plc (ITRM) Q4 2024 Earnings Call TranscriptFebruary 9, 2025 | seekingalpha.comIterum Therapeutics plc (NASDAQ:ITRM) Q4 2024 Earnings Call TranscriptFebruary 8, 2025 | insidermonkey.comIterum outlines ORLYNVAH's market potential with exclusivity through 2034February 8, 2025 | seekingalpha.comIterum Therapeutics files $150M mixed securities shelfFebruary 8, 2025 | markets.businessinsider.comEarnings call transcript: Iterum Therapeutics reports Q4 2024 results and stock surgesFebruary 8, 2025 | msn.comIterum Therapeutics Reports Fourth Quarter and Full Year 2024 Financial ResultsFebruary 7, 2025 | globenewswire.comIterum Therapeutics Q4 2024 Earnings PreviewFebruary 6, 2025 | msn.comIterum Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 7, 2025January 31, 2025 | globenewswire.comIterum Therapeutics Regains Full Nasdaq ComplianceNovember 21, 2024 | globenewswire.comIterum Therapeutics’ Strategic Advances with ORLYNVAH ApprovalNovember 16, 2024 | markets.businessinsider.comIterum Therapeutics plc (NASDAQ:ITRM) Q3 2024 Earnings Call TranscriptNovember 16, 2024 | msn.comIterum Therapeutics sees cash runway into 2025November 15, 2024 | markets.businessinsider.comIterum Therapeutics PLC (ITRM) Q3 2024 Earnings Call Highlights: Strategic Moves Amid Financial ...November 15, 2024 | finance.yahoo.comIterum Therapeutics plc (ITRM) Q3 2024 Earnings Call TranscriptNovember 14, 2024 | seekingalpha.comIterum Therapeutics Reports Third Quarter 2024 Financial ResultsNovember 14, 2024 | globenewswire.comA Look at Iterum Therapeutics's Upcoming Earnings ReportNovember 13, 2024 | benzinga.comFDA Approval Of Orlynvah For Urinary Tract Infections Marks Milestone For Iterum, Paves Way For New Strategic PartnershipsOctober 28, 2024 | finance.yahoo.com Get Iterum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ITRM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ITRM Media Mentions By Week ITRM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ITRM News Sentiment▼1.871.03▲Average Medical News Sentiment ITRM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ITRM Articles This Week▼11▲ITRM Articles Average Week Get the Latest News and Ratings for ITRM and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Iterum Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Fate Therapeutics News Scilex News Alpha Cognition News Zura Bio News Avalo Therapeutics News Compugen News Protalix BioTherapeutics News Protara Therapeutics News Corbus Pharmaceuticals News Oncobiologics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ITRM) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhat Are Some Strategies to Help Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iterum Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Iterum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access